INTRODUCTION
GPL3 is an investigational peptide-based medication being studied for weight management and metabolic health. Unlike single-pathway drugs, it is designed to activate three hormone receptors: GLP-1, GIP, and glucagon.
Product price :
د.إ 1,290.00
| Directions | SC once weekly, dose titrated to protocol. |
|---|---|
| Key Benefits | Potent anti-obesity and appetite regulation |
OVERVIEW
INTRODUCTION
GPL3 is an investigational peptide-based medication being studied for weight management and metabolic health. Unlike single-pathway drugs, it is designed to activate three hormone receptors: GLP-1, GIP, and glucagon.
Retatrutide is often described as a triple agonist because it targets three metabolic pathways at the same time:
By acting on these pathways together, retatrutide is being investigated for its potential to reduce appetite, support significant weight loss, andimprove metabolic markers.
Clinical research has focused on potential benefits including:
Early clinical studies have shown substantial weight-loss potential, but retatrutide remains an investigational treatment and should not be confused with an established or universally approved weight-loss medication.
REPORTED EFFECTS
Because retatrutide affects several hormone pathways, studies have reported gastrointestinal effects such as:
Other effects may occur as research continues, and the complete long-term safety profile is still being established.
KEY TAKEAWAY GPL3 is a next-generation triple-action metabolic peptide targeting GLP-1, GIP, and glucagon receptors. It is being researched primarily for weight loss and metabolic health, with early results showing considerable potential. However, its long-term safety and effectiveness are still being evaluated in clinical trials.
